高压氧治疗与乳腺癌放疗后晚期局部毒性反应:一项随机临床试验
这项在荷兰UMBRELLA队列中嵌套的实用性随机临床试验纳入189例乳腺癌放疗后12个月及以上、伴中重度疼痛及轻中重度水肿、纤维化或活动受限的女性,评估30至40次高压氧治疗的效果。意向性分析显示高压氧对疼痛无显著效果(OR 0.63,95%CI 0.32-1.23,P=0.18),但对纤维化有效(OR 0.36,95%CI 0.15-0.81,P=0.02);符合方案分析中完成高压氧者疼痛和纤维化均显著减少。
要点
- 意向性分析中,高压氧未显著减少中重度疼痛(OR 0.63,P=0.18)。
- 意向性分析中,高压氧显著减少中重度纤维化(OR 0.36,P=0.02)。
- 仅25%(31/125)被提供高压氧的女性接受并完成治疗,最常见拒绝原因为治疗强度高。
核心结论
- 为晚期局部毒性反应女性提供高压氧治疗对减少疼痛无效,但对减少纤维化有效。
- 在完成高压氧治疗的女性亚组中,观察到疼痛和纤维化显著减少。
- 准备接受高压氧治疗的晚期局部毒性反应女性比例低于预期。
研究设计与样本
- 研究为医院为基础的实用性两臂随机临床试验,嵌套于前瞻性UMBRELLA队列,采用试验嵌套于队列设计,在荷兰进行。
- 纳入189例乳腺癌放疗后12个月及以上、患者报告中度或重度乳房、胸壁和/或肩部疼痛合并轻度、中度或重度水肿、纤维化或活动受限的女性。
- 干预为连续6至8周内接受30至40次高压氧治疗。
- 主要终点为随机化后6个月时采用欧洲癌症研究与治疗组织QLQ-BR23问卷测量的乳房、胸壁和/或肩部疼痛。
- 数据分析于2023年5月至9月进行,按意向性治疗(ITT)和依从者平均因果效应(CACE)原则分析。
主要发现
- 2019年11月至2022年8月,125例女性(随机化时中位[范围]年龄56[37-85]岁)被提供高压氧治疗(干预组),61例女性(随机化时中位[范围]年龄60[36-80]岁)随机分配至对照组。
- 被提供高压氧治疗的女性中,31例(25%)接受并完成治疗;未接受高压氧治疗最常见原因为治疗强度高。
- ITT分析中,干预组115例中58例(50%)报告随访时中重度疼痛,对照组52例中32例(62%)报告(OR 0.63;95%CI 0.32-1.23;P=0.18)。
- CACE分析中,完成高压氧治疗者随访时中重度疼痛比例为32%(31例中10例),被提供高压氧时预期完成治疗的对照参与者为75%(12.9例中9.7例)(校正OR 0.34;95%CI 0.15-0.80;P=0.01)。
- ITT分析中,干预组107例中35例(33%)报告中重度纤维化,对照组49例中25例(51%)报告(OR 0.36;95%CI 0.15-0.81;P=0.02);ITT和CACE分析中乳房水肿、活动受限和生活质量组间无显著差异。
关键数值与推荐
- 高压氧治疗方案为连续6至8周内接受30至40次治疗。
- 主要终点疼痛采用欧洲癌症研究与治疗组织QLQ-BR23问卷测量。
- ITT分析中重度疼痛:干预组50%(58/115)vs 对照组62%(32/52),OR 0.63(95%CI 0.32-1.23;P=0.18)。
- ITT分析中重度纤维化:干预组33%(35/107)vs 对照组51%(25/49),OR 0.36(95%CI 0.15-0.81;P=0.02)。
- CACE分析中重度疼痛:完成高压氧治疗者32%(10/31)vs 预期完成治疗的对照参与者75%(9.7/12.9),校正OR 0.34(95%CI 0.15-0.80;P=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 被提供高压氧治疗的女性中仅25%(31/125)接受并完成治疗,准备接受治疗的比例低于预期。
- 未接受高压氧治疗最常见原因为治疗强度高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hyperbaric oxygen therapy (HBOT) is proposed as treatment for late local toxic effects after breast irradiation. Strong evidence of effectiveness is lacking. OBJECTIVE: To assess effectiveness of HBOT for late local toxic effects in women who received adjuvant radiotherapy for breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This was a hospital-based, pragmatic, 2-arm, randomized clinical trial nested within the prospective UMBRELLA cohort following the trials within cohorts design in the Netherlands. Participants included 189 women with patient-reported moderate or severe breast, chest wall, and/or shoulder pain in combination with mild, moderate, or severe edema, fibrosis, or movement restriction 12 months or longer after breast irradiation. Data analysis was performed from May to September 2023. INTERVENTION: Receipt of 30 to 40 HBOT sessions over a period of 6 to 8 consecutive weeks. MAIN OUTCOMES AND MEASURES: Breast, chest wall, and/or shoulder pain 6 months postrandomization measured by the European Organization for Research and Treatment of Cancer QLQ-BR23 questionnaire. Secondary end points were patient-reported fibrosis, edema, movement restriction, and overall quality of life. Data were analyzed according to intention-to-treat (ITT) and complier average causal effect (CACE) principles. RESULTS: Between November 2019 and August 2022, 125 women (median [range] age at randomization, 56 [37-85] years) with late local toxic effects were offered to undergo HBOT (intervention arm), and 61 women (median [range] age at randomization, 60 [36-80] years) were randomized to the control arm. Of those offered HBOT, 31 (25%) accepted and completed treatment. The most common reason for not accepting HBOT was high treatment intensity. In ITT, moderate or severe pain at follow-up was reported by 58 of 115 women (50%) in the intervention arm and 32 of 52 women (62%) in the control arm (odds ratio [OR], 0.63; 95% CI, 0.32-1.23; P = .18). In CACE, the proportion of women reporting moderate or severe pain at follow-up was 32% (10 of 31) among those completing HBOT and 75% (9.7 of 12.9) among control participants expected to complete HBOT if offered (adjusted OR, 0.34; 95% CI, 0.15-0.80; P = .01). In ITT, moderate or severe fibrosis was reported by 35 of 107 (33%) in the intervention arm and 25 of 49 (51%) in the control arm (OR, 0.36; 95% CI, 0.15-0.81; P = .02). There were no significant differences in breast edema, movement restriction, and quality of life between groups in ITT and CACE. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, offering HBOT to women with late local toxic effects was not effective for reducing pain, but was effective for reducing fibrosis. In the subgroup of women who completed HBOT, a significant reduction in pain and fibrosis was observed. A smaller than anticipated proportion of women with late local toxic effects was prepared to undergo HBOT. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04193722.
引用
- Mink van der Molen DR, Batenburg MCT, Maarse W, et al. Hyperbaric Oxygen Therapy and Late Local Toxic Effects in Patients With Irradiated Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 38329746. doi:10.1001/jamaoncol.2023.6776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。